Medpace (NASDAQ:MEDP) Issues FY 2025 Earnings Guidance

Medpace (NASDAQ:MEDP) updated its FY 2025 earnings guidance on Monday. The company provided earnings per share (EPS) guidance of 12.260-13.040 for the period, compared to the consensus estimate of 12.480. The company issued revenue guidance of $2.1 billion-$2.2 billion, compared to the consensus revenue estimate of $2.2 billion.

Medpace Stock Performance

Shares of Medpace stock opened at $288.99 on Tuesday. The company’s fifty day moving average is $317.57 and its two-hundred day moving average is $332.88. Medpace has a 1 year low of $269.08 and a 1 year high of $459.77. The company has a market capitalization of $8.74 billion, a P/E ratio of 22.88, a PEG ratio of 3.81 and a beta of 1.46.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Monday, April 21st. The company reported $3.67 EPS for the quarter, beating the consensus estimate of $3.06 by $0.61. Medpace had a return on equity of 51.48% and a net margin of 19.17%. The firm had revenue of $558.57 million during the quarter, compared to the consensus estimate of $528.38 million. During the same period in the prior year, the business earned $3.20 EPS. As a group, equities analysts expect that Medpace will post 12.29 earnings per share for the current year.

Wall Street Analyst Weigh In

MEDP has been the topic of several research analyst reports. Leerink Partnrs upgraded shares of Medpace to a “hold” rating in a research report on Monday, March 24th. TD Cowen downgraded shares of Medpace from a “buy” rating to a “hold” rating and dropped their target price for the company from $370.00 to $328.00 in a report on Monday, April 14th. Robert W. Baird lifted their price objective on Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a research report on Monday, January 27th. Mizuho lowered their target price on Medpace from $400.00 to $355.00 and set an “outperform” rating on the stock in a report on Wednesday, April 9th. Finally, Truist Financial reduced their price objective on Medpace from $347.00 to $333.00 and set a “hold” rating on the stock in a research report on Thursday, April 10th. Ten investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, Medpace presently has a consensus rating of “Hold” and an average price target of $357.50.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.